Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 All time
- Disclosed funding
- $19.1B 398 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| YB Yngvi BioCompany profile A Copenhagen crop-protection biotech developing protein-based pest-control products designed to target specific agricultural pests while reducing harm to beneficial insects and reliance on conventional pesticides. A Copenhagen crop-protection biotech developing protein-based pest-control products designed to target specific agricultural pests while reducing harm to beneficial insects and reliance on conventional pesticides. | €1.3M | BII Venture House convertible loanUndisclosed | Biotech, Agritech | Denmark | Investors | |
| PI PorMedTec, Inc.Company profile A biotechnology company producing gene-edited donor pigs for research and planned clinical trials in organ transplantation. A biotechnology company producing gene-edited donor pigs for research and planned clinical trials in organ transplantation. | ¥1B | FundingUndisclosed | Biotech | Japan | Investors | |
| V VaxdynCompany profile Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii. Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii. | €11M | Series A | Biotech | Spain | Investors | |
| AI ANRis, Inc.Company profile A biotechnology company developing siRNA medicines designed to suppress disease-causing mutations while preserving normal gene function. A biotechnology company developing siRNA medicines designed to suppress disease-causing mutations while preserving normal gene function. | ~¥220M | FundingUndisclosed | Biotech | Japan | Investors | |
| H HelogenCompany profile Helogen builds autonomous in-orbit manufacturing systems for biomaterials and biologics. Helogen builds autonomous in-orbit manufacturing systems for biomaterials and biologics. | $7.1M | Seed | Biotech, Space tech | United States | Investors | |
| MF MOA FoodtechCompany profile MOA Foodtech uses AI-guided fermentation to turn agricultural and food-processing byproducts into functional protein and ingredient products for food and pet-food manufacturers. Its models help select suitable microorganisms and process conditions for each feedstock; the company also offers custom development and modular systems for valorising starch-rich side streams. MOA Foodtech uses AI-guided fermentation to turn agricultural and food-processing byproducts into functional protein and ingredient products for food and pet-food manufacturers. Its models help select suitable microorganisms and process conditions for each feedstock; the company also offers custom development and modular systems for valorising starch-rich side streams. | €3.3M | €3.3 million financing roundUndisclosed | Biotech, Foodtech | Spain | Investors | |
| MT Metagen TherapeuticsCompany profile A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation. A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation. | ¥190M | Series B extension (first close)Series B | Biotech | Japan | Investors | |
| S Science4BeautyCompany profile A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels. A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels. | PLN 7M | Series A | Biotech | Poland | Investors | |
| SM Superluminal MedicinesCompany profile Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity. Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity. | $60M | Series B | Biotech | United States | Investors | |
| T TensiveCompany profile Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy. Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy. | ≤€20M | Convertible venture debtUndisclosed | Biotech, Healthtech | Italy | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.